GlassScriptPhysician profile
Lee Voulters
NPI 1669417705
$9,107.84
in general payments reported to CMS, 2019-2025
50 companies · $1,107 in 2025
The $1,107 reported for 2025 was more than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,874 · 2020: $610 · 2021: $885 · 2022: $1,306 · 2023: $1,760 · 2024: $1,565 · 2025: $1,107.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,432.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,432.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,265.44 | 2021-2025 | Botox, Ubrelvy, Qulipta |
| Acadia Pharmaceuticals INC | $1,021.22 | 2019-2025 | Nuplazid |
| Novartis Pharmaceuticals Corporation | $874.55 | 2019-2025 | |
| Allergan, INC. | $620.47 | 2019-2022 | |
| Pfizer INC. | $479.34 | 2022-2025 | |
| Horizon Therapeutics Plc | $435.30 | 2022-2023 | Uplizna |
| Teva Pharmaceuticals USA, INC. | $431.88 | 2019-2025 | Austedo, Austedo Xr, Austedo Xr |
| Ucb, INC. | $425.40 | 2019-2025 | Nayzilam, Zilbrysq, Briviact |
| Amgen INC. | $295.87 | 2019-2025 | Uplizna |
| Argenx US, INC. | $268.09 | 2022-2025 | Vyvgart Hytrulo, Vyvgart |
| Sk Life Science, INC. | $238.01 | 2020-2022 | |
| Supernus Pharmaceuticals, INC. | $222.24 | 2019-2020 | |
| Sunovion Pharmaceuticals INC. | $186.01 | 2019-2021 | |
| Emd Serono, INC. | $171.91 | 2019-2025 | Mavenclad |
| Alexion Pharmaceuticals, INC. | $159.28 | 2019-2025 | Ultomiris |
Show all 50 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lundbeck LLC | $157.41 | 2019-2025 | Vyepti, Rexulti |
| Eisai INC. | $137.02 | 2019-2025 | |
| Octapharma USA, INC. | $122.37 | 2022-2024 | Panzyga |
| Ge Healthcare | $119.50 | 2019-2025 | |
| Celgene Corporation | $117.54 | 2022-2025 | Zeposia |
| Jazz Pharmaceuticals INC. | $113.67 | 2019-2023 | |
| Mdd US Operations, LLC | $106.26 | 2019-2022 | |
| Lilly USA, LLC | $94.67 | 2019-2024 | Emgality |
| Neurocrine Biosciences, INC. | $89.75 | 2019-2021 | |
| Genentech USA, INC. | $81.73 | 2019-2023 | Ocrevus, Evrysdi |
| Genzyme Corporation | $80.33 | 2019-2020 | |
| Biohaven Pharmaceuticals, INC. | $79.83 | 2021 | |
| Mallinckrodt Enterprises LLC | $76.09 | 2019 | |
| Biohaven Pharmaceutical Holding Company LTD. | $70.12 | 2022 | |
| Mallinckrodt Hospital Products INC. | $65.59 | 2020-2025 | Acthar |
| Janssen Pharmaceuticals, INC | $58.55 | 2022 | |
| Biogen, INC. | $42.44 | 2019-2021 | |
| Amneal Pharmaceuticals LLC | $40.39 | 2019-2024 | Rytary, Ongentys |
| Vanda Pharmaceuticals INC. | $40.22 | 2024-2025 | Ponvory |
| Adamas Pharmaceuticals, INC. | $38.33 | 2019-2020 | |
| Avanir Pharmaceuticals, INC. | $31.51 | 2021-2022 | |
| Abbott Laboratories | $31.27 | 2021 | |
| Chiesi USA, INC. | $26.89 | 2019-2025 | Cleviprex |
| Otsuka America Pharmaceutical, INC. | $19.26 | 2024 | Rexulti |
| Cycle Pharmaceuticals INC | $19.21 | 2025 | Tascenso Odt, Bafiertam |
| Kyowa Kirin, INC. | $19.08 | 2023 | Nourianz |
| Grifols USA, LLC | $18.34 | 2023 | Gamunex-C |
| Csl Behring | $18.22 | 2024 | Hizentra |
| Boston Scientific Corporation | $17.51 | 2024 | |
| Astrazeneca Pharmaceuticals LP | $15.78 | 2021 | |
| Neurelis, INC. | $15.32 | 2022 | |
| Assertio Therapeutics, INC. | $15.15 | 2019 | |
| Kedrion Biopharma, INC. | $15.01 | 2024 | Rhogam Ultra-Filtered Plus, Albuked, Kedrab |
| Kls-Martin L.P. | $13.82 | 2022 | |
| Sumitomo Pharma America, INC. | $4.65 | 2023 | Aptiom |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lee Voulters listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.